By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a




Company News
TapImmune (TPIV) Amends Phase II Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments 8/8/2017 9:47:54 AM
TapImmune (TPIV) Reaches 50% Patient Enrollment Benchmark In Phase II Study Of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer 6/27/2017 8:07:09 AM
TapImmune (TPIV) Enters Into Definitive Agreements To Raise $6.82 Million In A Private Placement From Accredited Investors And From The Exercise Of Warrants By Existing Institutional Investors 6/22/2017 7:29:38 AM
TapImmune (TPIV) Provides First Quarter 2017 Corporate And Clinical Update 6/1/2017 6:13:41 AM
TapImmune (TPIV) To Provide First Quarter 2017 Business Update Conference Call And Webcast 5/18/2017 10:32:01 AM
Richard Kenney, MD, FACP, Joins TapImmune (TPIV) To Lead The Clinical Development Program 5/1/2017 7:33:52 AM
TapImmune (TPIV) COO Resigns To Pursue New Opportunities, Effective Immediately 5/1/2017 5:59:21 AM
TapImmune (TPIV) Provides Year End 2016 Corporate and Clinical Update 3/15/2017 10:04:44 AM
TapImmune (TPIV) Announces Fully Funded Phase II Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer 3/14/2017 8:24:51 AM
TapImmune (TPIV) Advances TPIV 200 Phase II Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review 2/15/2017 7:45:09 AM